Parenteral nutrition

From WardWiki - Foundation Doctor Helper

(Redirected from Total Parenteral Nutrition)
Jump to: navigation, search

Contents

Indication

Parenteral nutrition (PN) may be indicated in the following circumstances:

Disadvantages

The sole advantage of TPN is the ability to feed a patient while there is gut failure or there is need to rest the gut while an enterocutaneous fistula heals. There are many more reasons NOT to consider TPN than to consider it and these are listed below:

Starting Parenteral Nutrition

Patients starting PN are at risk of developing refeeding syndrome and PN should be started slowly to try & minimise complications (NICE guidelines 2006). All patients should be given Pabrinex before starting PN See page 4 & then daily for up to 5 days in the most severely undernourished. Patients should be prescribed half a Kabiven K11 Standard 1 daily for the first 48 hours and monitored carefully for refeeding syndrome with daily bloods for U&E, Ca, Mg, PO4 and IV supplementation as required.

Patients will need additional fluid & electrolyte supplementation during this time. Please be cautious in the quantity and use of additional IV fluid. Use normal saline or Hartmann’s Solution in place of Dextrose or 5% Dextrose as the PN solution will provide a high concentration of glucose once commenced. DO NOT OVERLOAD THE PATIENT by failing to include TPN volume on the fluid balance chart.

Refeeding Syndrome

Refeeding syndrome is defined as severe fluid and electrolyte shifts and related metabolic implications in malnourished patients undergoing refeeding (Solomon and Kirby, 1990). Refeeding syndrome is caused by a switch from starvation to anabolism, with glucose as the major energy source.

Metabolic abnormalities include:

These abnormalities can lead to cardiac, respiratory, neuromuscular, haematologic, hepatic and gastrointestinal complications. If untreated they can be fatal.

Patients at high risk of refeeding syndrome include: Patients with one of the following:

OR Patients with two or more of the following:

(NICE 2006)

Patients at high risk of refeeding syndrome should receive adequate doses of thiamine, Vitamin B and multivitamins/trace elements immediately before and for the next three days of feeding (NICE 2006) or for longer is the patient is severely malnourished). This may also be administered intravenously once daily as a pair of Pabrinex ® intravenous high potency (vitamin B & C injection BPC) ampoules. These contain 250 mg of thiamine. Ensure ampoules are for intravenous administration. Mix 1 pair (ampoules 1 & 2) together in a syringe. Add to a minimum of 50 -100ml normal saline or glucose 5% and infuse over 30 minutes.

Caution: Repeated injections of Pabrinex or large doses: >400mg, have been associated with anaphylaxis. Facilities for treating anaphylactic reactions should be available. Patients on enteral feeds should receive oral thiamine 200-300mg/day, vitamin B co-strong 1-2 tablets tds and a balanced multivitamin/trace element supplement once daily. For those unable to swallow safely may have oral thiamine tablets crushed and dispersed in water and Vigranon B Syrup (Oral vitamin B complex) given via the enteral tube feeding.

Patients at high risk of refeeding syndrome require oral/enteral/intravenous supplements of potassium (likely requirement 2-4mmol/kg/day), phosphate (likely requirement 0.3-0.6mmol/kg/day) and magnesium (likely requirement 0.4mmol/kg/day). In such patients the FY1 should monitor bloods (U & E’s, Ca, Mg & Phosphate) daily and correct abnormalities where necessary.

Nutrition support should be started slowly in seriously ill patients requiring enteral feeding. It should be started no more than 50% of the estimated target energy and protein requirements and be built up to meet their full needs over 24-48 hours. In patients at high risk of refeeding syndrome feed should start at a maximum of 10kcal/kg/day increasing slowly to full requirements over 4-7 days. In extreme cases use only 5kcal/kg/day restoring circulatory volume and monitoring fluid balance and overall clinical status closely. In all patients full requirements of fluids, electrolytes, vitamins and minerals should beprovided from the outset of feeding.

Replacement Therapy in Refeeding Syndrome

(Adapted from Dewar & Horvath, 2001, Terlevich et al. 2003, NICE 2006) The following are guidelines only and should not replace the clinical judgement of the doctor and pharmacist. NICE (2006) no longer recommends delaying the start of the feed in patients at risk of refeeding syndrome to replace electrolytes – but does recommend starting the feed cautiously whilst replacing the electrolytes. All patients at risk of refeeding syndrome should be given oral thiamine or Pabrinex before starting the feed.

Low phosphate

Serum phosphate <0.5mmol/l represents severe deficiency and needs correcting regardless of the route of feeding. Serum phosphate >0.5mmol/l in patients on enteral feeding - phosphate can be corrected with the use of oral phosphate preparations e.g. Phosphate-Sandoz (effervescent tablets – 1 tablet = 16.1 mmol phosphate).

Correcting phosphate intravenously

Infuse 500ml Phosphate Polyfusor (giving 50mmol phosphate, 81mmol sodium, 9.5mmol potassium) through a dedicated cannula over 24 hours Monitor phosphate levels daily Further infusions of the phosphates polyfusor can be given (as above) if phosphate is still <0.5mmol/l. (Note IV phosphate should not be given to hypocalcaemic patients).

Low Magnesium

Serum magnesium <0.6mmol/l requires IV replacement. Serum magnesium levels 0.6 – 0.8 mmol/l in patients on enteral feeding may be supplemented orally/enterally using magnesium glycerophosphate tablets (4 mmol magnesium per tablet) or Magnesium glycerophosphate liquid 1mmol/ml.) The initial dose is 1-2 tablets 3 times a day, up to 3 tablets four times a day. The tablets can be dispersed in water for tube administration. For tube administration: Flush the tube well before and after magnesium or the drug may precipitate and block the tube. N.B. these preparations are unlicensed, therefore, the doctor must sign a disclaimer form

Correcting Magnesium intravenously

Give 8-12mmol magnesium (4 ml 50% magnesium sulphate injection) in 100 ml 5% glucose or 0.9% sodium chloride over eight hours, or 60 minutes in a HDU / ITU The second dose should be 8-12 mmol (20 ml 50% magnesium sulphate) in a minimum of 100 ml over 20 hours. Recheck magnesium levels. Higher infusions than this do really require specialist input.

Incompatabilties

Magnesium or calcium, & phosphate may be given simultaneously via the intravenous route however these should be given via separate cannula. Ideally these should be placed in opposing limbs as precipitation of insoluble phosphates results.

Hyperglycaemia during Parenteral nutrition and insulin treatment

Parenteral nutrition will be given continuously and hence need for gylcaemic control is contant and predictable.

Management of known diabetics during parenteral nutrition

When commencing a parenteral feed on a diabetic patient, hyperglycaemia occurs within a few hours and can be marked. If no concomitant insulin treatment is started patients can become grossly polyuric and dehydrated, and may progress to HONK (hyper-osmolar nonketosis)in type 2 diabetics, or DKA (diabetic ketoacidosis) in type 1 diabetics.

Reintroduction of enteral feeding

This is desired to aid discharge and use the working gut. There are many advantages to using the gut rather than TPN and these should be sought as early as possible. Reintroduction may be slow and unsteady in some patients and close support from a dietician is essential to success. In diabetic patients, further input is required as listed below.

Sources

Luton & Dunstable Hospital NHS Foundation Trust - Guidelines for PARENTERAL/ENTERAL NUTRITION

Personal tools
Namespaces
Variants
Actions
Main info
Communicate
Toolbox